Alzheimer's disease. Markers in the cerebrospinal fluid in support of the pathogenic hypotheses;MALADIE D'ALZHEIMER. LES MARQUEURS DANS LE LIQUIDE CEPHALORACHIDIEN

Presse Medicale

Volumn 27, Issue 15, 1998, Pages 731-738

  Blain, H ^a   Jeandel, C ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; BIOCHEMICAL MARKER; NEUROTRANSMITTER;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN BIOPSY; BRAIN TISSUE; CEREBROSPINAL FLUID; EARLY DIAGNOSIS; HUMAN; METHODOLOGY; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; SENILE PLAQUE;

ALZHEIMER DISEASE; BRAIN; BRAIN CHEMISTRY; HUMANS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; RECEPTORS, CHOLINERGIC; SENILE PLAQUES;

EID: 0032542984     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hartikainen P, Reinikainen KJ, Soininen H, Sirvio J, Soikkeli R, Riekkinen PJ. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm Park Dis Dement Sect 1992 ; 4:53-68.
2. O'Connor DT, Kailasam MT, Thal LJ. Cerebrospinal fluid chromogranin A is unchanged in Alzheimer dementia. Neurobiol Aging 1993 ; 14:267-9.
3. Blennow K, Wallin A, Gottfries CG et al. Significance of decrease lumbar CSF of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging 1992 ; 13:107-13.
4. Molchan SE, Hill JL, Martinez RA et al. CSF somatostatin in Alzheimer's disease and major depression: relationship to hypothalamic-pituitary-adrenal axis and clinical measures. Psychoneuroendocrinology 1993 ; 18:509-19.
5. Gunnersen D, Haley B. Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: a potential diagnostic biochemical marker. Proc Natl Acad Sci USA 1992 ; 89:11949-53.
6. Edvinsson L, Minthon L, Eckman R, Gustafson L. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. Dementia 1993 ; 4:167-71.
7. Sunderland T, Berrettini WH, Molchan SE et al. Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease. Biol Psychiatry 1991 ; 30(1):81-7.
8. Munroe WA, Southwick PC, Chang L et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci 1995 ; 25:207-17.
9. Van Nostrand WE, Wagner SL, Haan J, Bakker E, Roos SA. Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis-Dutch type share a decrease in cerebrospinal fluid levels of amyloid beta-protein precursor. Ann Neurol 1992 ; 32:215-8.
10. Urakami K, Okada A, Ohno K et al. Amyloid beta precursor with Kunitz-type protease inhibitor domains (APPI) in cerebrospinal fluid and APPI mRNAs in cultured skin fibroblasts of patients with Alzheimer's disease. Tohoku J Exp Med 1994 ; 174(3):199-207.
11. Southwick PC, Yamagata SK, Echols CL et al. Assesment of amyloid b protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem 1996 ; 66:259-65.
12. Pirttilä T, Kim KS, Mehta PD, Wisniewski HM, Frey H. Immunoreactivity against amyloid beta peptide (Aβ) is decreased in the cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD). Neurology 1994 ; 44(suppl. 2):A206.
13. Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL. Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat Med 1995 ; 1:829-32.
14. Ghiso J, Matsubara I, Koudinov A et al. The cerebrospinal fluid soluble form of Alzheimer's amyloid beta, is complexed to SP40(40) (ApoJ), an inhibitor of the complement-attack complex. Biochem J 1993 ; 293:27-30.
15. Merched A, Blain H, Visvikis S, Herbeth B, Jeandel C, Siest G. Cerebrospinal fluid apolipoprotein E level is increased in late onset Alzheimer's disease. J Neurol Sci 1996 ; 5146.
16. Blain H, Merched A, Visvikis S, Siest G, Jeandel C. Apolipoprotein E level in cerebrospinal fluid increases with aging. JAGS 1997 ; 45:1536.
17. Blennow K, Davidsson P, Wallin A, Gottfries CG, Svennerholm L. Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia. Int Psychogeriatr 1994 ; 6:13-22.
18. Schwagerl AL, Mohan PS, Cataldo AM. Elevated levels of yhe endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer's disease. J Neurochem 1995 ; 64:443-6.
19. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995 ; 202:17-20.
20. Pirttilä T, Mehta PD, Frey H, Wisniewski HM. a1-anti-chymotrypsin and 1l-1b are not increased in CSF or serum in Alzheimer's disease. Neurobiol Aging 1994 ; 15:313-7.
21. Rao JS, Chen M, Festoff BW. Plasminogen activator inhibitor 1, the primary regulator of fibrinolysis, in normal human cerebrospinal fluid. J Neurosci Res 1993 ; 34:340-5.
22. Mc Rae A, Dahlström A, Polinsky R, Ling EA. Cerebrospinal fluid microglial antibodies: potential diagnostic markers for immune mechanisms in Alzheimer's disease. Behavioural Brain Research 1993 ; 57:225-34.
23. Tohgi H, Abe T, Nakanishi M, Hamato F, Sasaki K, Takahashi S. Concentrations of α-tocopherol and its quinone derivative in cerebrospinal fluid from patients with vascular dementia of Binswanger type and Alzheimer type dementia. Neurosci Lett 1994 ; 174:73-6.
24. Bracco F, Scarpa M, Rigo A, Battistin L. Determination of superoxide dismutase activity by the polarographic method of catalytic currents in the cerebrospinal fluid of aging brain and neurologic degenertative diseases. Proc Soc Exp Biol Med 1991 ; 196:36-41.
25. Kuiper MA, Mulder C, Van Kamp GJ, Scheltens P, Wolters EC. Cerebospinal fluid ferritin levels of patients with Parkinson's disease, alzheimer's disease, and multiple system atrophy. J Neural Transm 1994 ; 7:109-14.
26. De La Monte SM, Volicer L, Hauser SL, Wands JR. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1992 ; 32(6):733-42.
27. Crols R, Saerens J, Noppe M, Lowenthal A. Increased FgAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome. J Neurol 1986 ; 233:157-60.
28. Tham A, Nordberg A, Grissom FE, Carlsson-Skwirut C, Viitanen M, Sara VR. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the alzheimer type. J Neural Transm Park Dis Dement Sect 1993 ; 5:165-76.
29. Kittur SD, Adler WH, Martin GR, Schapiro MB, Rapoport SI, GunZler V. Laminin concentrations in serum and cerebrospinal fluid in aging and Alzheimer's disease. Int J Dev Neurosci 1993 ; 11:95-9.
30. Du Yan S, Zhu H, Fu J et al. Amyloid-ß peptide-receptor for advanced glycation and product interaction elicits neuronal expression of macophage - colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 1997 ; 94:5296-301.
31. Blennow K, Davidsson P, Wallin A, Fredman P, GottFries CG, Mansson JE, Svennerholm L. Differencies in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging. Aging 1992 ; 4:301-6.
32. Fredman P, Wallin A, Blennow K, Davidsson P, GottFries CG, Svennerholm L. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Acta Neurol Scand 1992 ; 85:103-6.
33. Basun H, Forssell LG, Wetterberg L, Winblad B. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1991 ; 3(4)231-58.
34. Subhash MN, Padmashree TS, Srinivas KN, Subbakrishna DK, Shankar SK. Calcium and phosphorus levels in serum and CSF in dementia. Neurobiol Aging 1991 ; 12:267-9.
35. May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI. Cerebrospinal fluid production is reduced in healthy aging. Neurol 1990 ; 40:500-3.